AzTrials
AzTrials

ObesityNCT02480179

CNS Modification of Food Craving by Neurofeedback

A study testing H.E.G. (hematoencephalography) based neurofeedback in people with Obesity, run by Sheba Medical Center.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The investigators plan to evaluate H.E.G. (Hematoencephalography) modality in brain modulation of appetite and food craving in a randomized controlled study. The H.E.G. will serve as the neurofeedback modality while the functional brain imaging will enable assessment and hopefully validation of changes brain activity… Read more about this study

Who is it for?
Ages 20 to 50 years, men onlyHealthy volunteers can take part
Conditions the study is for
Obesity
What is being tested?
H.E.G. (hematoencephalography) based neurofeedback
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
No sites listed yet
Study dates
Jun 2015to Apr 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Right handed BMI in the range of 28-35kg/m2

Who cannot join

  • Current or past history of any major psychiatric disorder
  • Major medical or neurological disorders
  • Exposure to drugs likely to influence cerebral blood flow or neurological function within 3 weeks
  • History of drug or alcohol abuse
  • General MRI exclusion criteria

Trial locations and contacts

No sites are listed yet.

Ruth Percik, MD contact

972-3-5302021

ruthpercik@gmail.com

Jenny Cina, Ph.D contact

972-3-5308493

jennycinaphd@gmail.com

About this study

The investigators plan to evaluate H.E.G. (Hematoencephalography) modality in brain modulation of appetite and food craving in a randomized controlled study. The H.E.G. will serve as the neurofeedback modality while the functional brain imaging will enable assessment and hopefully validation of changes brain activity related to food craving and self-control. H.E.G. is a relatively new neurofeedback technique which similar to fMRI, is based on changes in blood oxygenation level as a result of regional brain activation. The unique advantage of this technology regarding our enterprise is that it inheritably samples the two brain areas that are in our focus of interest: the superior orbito-frontal cortex (OFC) which Involved in self-control and reward processing, and the anterior cingulate cortex (ACC) which processes cognitive and emotional information. The investigators will combine HRV (Heart rate variability) biofeedback, which is a well-established treatment form in the investigators therapeutic sessions and will correlate functional neuroimaging with behavioral, anthropometric and laboratory data.

The intervention name is: Measurements of blood flow changes within the brain and online visual feedback to the participant by a H.E.R. (Hematoencephalography) N.I,R (Near Infra Red sensor) sensor made by MindMedia, The Netherlands and a NEXUX4 Hardware, Bluetooth unit, Bio Trace Plus software made by MindMedia, The Netherlands.

Hypothesis: The neurofeedback practice sessions are expected to facilitate improved control of blood flow to frontal brain areas, as a marker of brain activity in these areas

Read the detailed description

CNS Modification of Food Craving by Neurofeedback Study Protocol Research Plan and Methodology

The investigators's goal is to modulate food craving and eating behavior among overweight and obese participants using and interventional neurofeedback program. During the study period, each participant will go through 10 neurofeedback sessions, two sessions per week, over a five-week period. In addition, each participant will go through two functional MRI sessions, the first session, before the neurofeedback intervention, to document baseline neurocognitive response to food stimuli using a specified paradigm and the second - after completion of the neurofeedback series, in order to evaluate changes in C.N.S. response to food.

Subjects: 6 overweight and obese participants will be participate in our pilot study and will go through 2 fMRI sessions, 10 H.E.G. sessions and 3 anthropometric and metabolic evaluations during one year intervention and follow-up.

Study Design: In the investigators's single arm pilot study participants will go through a series of neurofeedback sessions with psychological, anthropomorphic, and laboratory evaluation taken before and after intervention.

Baseline questioners: Baseline assessment will include completion of a combined questionnaire that will address a spectrum eating behavior traits, including hunger and craving, addiction, impulsivity, binge eating, addiction, impulsivity, hedonic eating and externally driven eating14-23.

Anthropomorphic measurements: Height, weight, waist circumference and BMI will be measured before intervention. Weight and calculated BMI will be documented twice more: at week 7-8, soon after accomplishing the Neurofeedback sessions series and at week 12.

The investigators intend to call participants 6 and 12 months after study start and ask for their current weight.

Blood samples: Gut peptides and hormones that are known to parallel weight changes will be measured in the first and last visits including: leptin, morning cortisol, TSH, Ft4 and TT3. In addition, before each fMRI session we will evaluate "satiety profile" by documenting levels of Ghrelin, PYY, c-peptide and insulin.

Functional MRI sessions Experimental Paradigm Based on current knowledge regarding brain areas involved in food craving, the investigators defined two ROIs (regions of interest) that correspond with the introspective tasks in the H.E.G. neurofeedback sessions, one area in the superior orbitofrontal cortex (sOFC.) bilaterally and the second: the anterior cingulated cortex (ACC) bilaterally. Each ROI will be mapped in a block design paradigm (7:22 min) in which visual food stimuli will be shown alternately with neutral visual stimuli (neutral objects) and fixation (8 cycles, 54sec each including 3 blocks, 18s each of fixation, neutral objects, and food stimuli).

For the investigator's specific modulation goal, the suitable in-scanner satiety status is "half satiated". On one hand, hunger activates brain circuits involved in homeostatic appetite while, on the other hand complete satiety will shut down any food craving. For that purpose, participants will be asked to time their meals in order to start the session 1-2 hours after a medium-large meal. The investigators will document in detail the last meal (timing, content, estimated caloric value) and explore correlative parameters in the hormonal profile. Participants will be asked to rate their hunger, satiety, fullness and prospective eating in visual analogue scales: graphic questioners that are commonly used and well validated in eating behavior research field.

fMRI data acquisition: Functional scanning will be performed using a 3 Tesla whole body MRI system (GE EXITE HDxt, most updated version 14 M5) equipped with 8-channel head coil. Each scan will be acquired using a standard gradient echo planar imaging (EPI) sequence. After each volume is acquired, it will be automatically transferred in DICOM format from the MRI scanner computer to a separate computer for in-scan processing.

fMRI data processing: Online RT-fMRI processing will be made possible via a fast connection between the MRI scanner and the analysis/display computer. Turbo-Brain Voyager (TBV) 2.0 software (Brain Innovation, Maastricht, the Netherlands) will be used to perform real-time in-scan processing. TBV is capable of incrementally computing statistical maps based on General Linear Model (GLM) and event-related averages.

Off-line fMRI analysis:

Off-line analysis will be conducted to all data collected. Off-line analysis will be performed using Statistical Parametric Mapping software 8 (SPM8. The Welcome Department of Cognitive Neurology, London, UK). While MarsBar toolbox (the Marseille region of interest toolbox for SPM) will be used for ROI analysis.

Neurofeedback sessions Participants will undergo 10 H.E.G. sessions, twice weekly, over 5 weeks of intervention. They will be instructed to come to sessions in a "half-satiated" condition in order to focus on hedonic/emotional brain circuits involved in eating behavior rather than physiological circuits, based on the "real", physiological hunger. Participants will be given introspective tasks of mindfulness, increased sense of self-control and reduced food craving and will be instructed to attempts augmentation for visual feedback. These tasks correlate with modulation of our ROIs: Increase self-control - is adjusted to increase activity in the superior orbitofrontal cortex (sOFC) whereas suppressing food craving is adjusted to modification of neural activity in the anterior cingulated cortex (ACC) bilaterally. Successive feedback regarding changes in activity in this region will be given analogically with a thermometer with bars above baseline level of activation colored in red while those below baseline colored blue. Thermometer bars are constantly updated with a minimal inherent delay.

Conditions
Obesity
Being tested
H.E.G. (hematoencephalography) based neurofeedback
Keywords
functional MRI, appetite, neurofeedback
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • H.E.G. (hematoencephalography) based neurofeedbackDevice

    Also called ProComp2 - 2 Channel Biofeedback & Neurofeedback System w/ BioGraph Infiniti Software - T7400M

    H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.

Study groups in NCT02480179
Study groupRoleWhat they receive
single arm pilot feasibility studyExperimentalHematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
Receives: Device: H.E.G. (hematoencephalography) based neurofeedback

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Increase brain activity in frontal brain areas

    Measured: 7 weeks

Secondary outcomes (4)
  1. Increased activation of superior frontal brain regions and middle temporal regions in response to food stimuli, in the second fMRI session, perforemed after the neurofeedback sessions, compared to baseline session

    Activation of superior frontal brain regions and middle temporal regions in response to food stimuli, known to correlate with inhibition, self control and executive functions.

    Measured: 7 weeks

  2. Behavioural measures

    Increased scores of self control and inhibition and decreased scores of binge eating and emotional eating on questionnaires.

    Measured: 12 months

  3. Anthropometric measures

    weight loss according to follow-up 6 and 12 months after intervention.

    Measured: 12 months

  4. Number of participants with adverse events

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2015 (estimated)
  2. Study startJun 2015
  3. Primary completionOct 2015 (estimated)
  4. Study completionApr 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
5 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02480179
Sponsor's protocol ID
1164-14-SMC
Status last verified
Jun 2015
First submitted
28 May 2015
Last updated
24 Jun 2015
Results posted
No
Data monitoring committee
No

Publications

  • Percik R, Cina J, Even B, Gitler A, Geva D, Seluk L, Livny A. A pilot study of a novel therapeutic approach to obesity: CNS modification by N.I.R. H.E.G. neurofeedback. Clin Nutr. 2019 Feb;38(1):258-263. doi: 10.1016/j.clnu.2018.01.023. Epub 2018 Feb 15.

    PubMed 29428788

Questions about this trial

What is this clinical trial studying?

A study testing H.E.G. (hematoencephalography) based neurofeedback in people with Obesity, run by Sheba Medical Center.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ruth Percik, MD (972-3-5302021, ruthpercik@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Increase brain activity in frontal brain areas (time frame: 7 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02480179, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in